Analysts expect that Corium International Inc (NASDAQ:CORI) will post earnings of ($0.39) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Corium International’s earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.33). Corium International reported earnings of ($0.43) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 9.3%. The business is scheduled to issue its next earnings report on Thursday, August 2nd.
On average, analysts expect that Corium International will report full-year earnings of ($1.59) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.50). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.74) to ($1.09). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Corium International.
Corium International (NASDAQ:CORI) last released its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Corium International had a negative net margin of 156.05% and a negative return on equity of 273.01%. The company had revenue of $10.06 million during the quarter, compared to analyst estimates of $7.07 million.
A number of equities research analysts recently issued reports on the stock. BidaskClub raised shares of Corium International from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 13th. Zacks Investment Research cut shares of Corium International from a “buy” rating to a “hold” rating in a research note on Thursday, April 5th. ValuEngine raised shares of Corium International from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Corium International in a research note on Friday, May 18th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Corium International currently has a consensus rating of “Buy” and an average price target of $13.00.
Corium International opened at $8.90 on Friday, MarketBeat reports. Corium International has a 1 year low of $6.97 and a 1 year high of $13.93. The firm has a market capitalization of $320.02 million, a P/E ratio of -5.43 and a beta of 1.54. The company has a debt-to-equity ratio of 1.89, a quick ratio of 7.95 and a current ratio of 8.11.
A number of hedge funds have recently made changes to their positions in the business. Iguana Healthcare Management LLC lifted its holdings in Corium International by 22.2% in the 1st quarter. Iguana Healthcare Management LLC now owns 110,000 shares of the biopharmaceutical company’s stock valued at $1,262,000 after purchasing an additional 20,000 shares in the last quarter. Citadel Advisors LLC purchased a new position in Corium International in the 1st quarter valued at $455,000. Franklin Resources Inc. lifted its holdings in Corium International by 115.3% in the 1st quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after purchasing an additional 1,102,910 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Corium International by 1,746.7% in the 1st quarter. JPMorgan Chase & Co. now owns 96,935 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 91,686 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in Corium International by 127.9% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 196,000 shares of the biopharmaceutical company’s stock valued at $2,248,000 after purchasing an additional 110,000 shares in the last quarter. Institutional investors own 94.79% of the company’s stock.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.